InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Slated to Report Preclinical Data on Lead Candidate at Upcoming Scientific Congresses
April 21, 2022
VistaGen Therapeutics (NASDAQ: VTGN), a late clinical-stage, central nervous system (“CNS”) focused biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders, will be presenting its research at upcoming gatherings for two prestigious organizations. Company researchers will discuss preclinical data supporting the differentiated mechanism of action (“MOA”) […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN), AffaMed Announce Substantial Progress Toward Initiating PALISADE Global Trial
April 12, 2022
VistaGen (NASDAQ: VTGN) and AffaMed Therapeutics have announced completion of regulatory preparations to initiate PALISADE Global, a phase 3 clinical trial to evaluate the efficacy, safety and tolerability of VistaGen’s PH94B (referred to by AffaMed as “AM005”) for the acute treatment of anxiety in adults with social anxiety disorder (“SAD”), in the U.S. and China. […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at Maxim Group 2022 Virtual Growth Conference
March 24, 2022
VistaGen (NASDAQ: VTGN), a late clinical-stage, neuro-focused biopharmaceutical company striving to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system (“CNS”) disorders, today announced that its Chief Executive Officer Shawn Singh will participate in a fireside chat with Maxim Analyst Jason McCarthy, Ph.D. The chat is slated to take […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q3 2022 Financial Numbers, Corporate Update
February 11, 2022
VistaGen Therapeutics (NASDAQ: VTGN), a company developing therapeutics to transform the treatment paradigm for patients suffering from anxiety, depression and other central nervous system disorders, has reported its third-quarter 2022 financial and business status. Highlights of the report include the advancement of VTGN’s late-stage PH94B clinical program, including progress toward topline data readouts for phase […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Release FY 2022 Q3 Financial Results, Host Conference Call
February 7, 2022
VistaGen (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders. The company has announced that it will host a conference call and webcast at 2:00 p.m. Pacific Time on Thursday, […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) CEO to Present at the Jefferies London Healthcare Conference on November 18
November 16, 2021
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that the company will participate in the upcoming Jefferies Virtual London Healthcare Conference. On Thursday, November 18, VistaGen’s Chief Executive Officer Shawn […]
Roth Capital Partners to Virtually Host 10th Annual Roth Technology Event
November 15, 2021
Event to Feature One-on-One Meetings Between Institutional Investors and Senior Company Management from Select Companies across a Variety of Technology Sub-Sectors NEWPORT BEACH, Calif., Nov 15, 2021 — via InvestorWire — Roth Capital Partners (Roth), a full-service investment bank renowned for serving emerging growth companies today announces that it will host the 10th Annual Roth Technology […]
Roth Capital Partners Provides Agenda Details of Inaugural AgTech Answers Event
November 11, 2021
Event to Feature Fireside Chat, Industry Panel and One-on-One Meetings Between Institutional Investors and Senior Company Management NEWPORT BEACH, Calif., Nov 11, 2021 — via InvestorWire — Roth Capital Partners (Roth), a full-service investment bank renowned for serving emerging growth companies is pleased to announce the agenda for the Inaugural AgTech Answers Virtual Event. “AgTech […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q2 2022 Financial Numbers, Corporate Highlights
November 11, 2021
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has reported its second-quarter 2022 financial and business status. Highlights of the reports include that progress on […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Call, Release Q2 2022 Financial Report and Development Update
November 4, 2021
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has scheduled a Nov. 10, 2021, conference call and webcast. During the call, which is slated to […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Expands Clinical Development of PH94B with Initiation of Phase 2A AjDA Trial
October 14, 2021
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the initiation of a phase 2A clinical trial to evaluate the efficacy, safety and tolerability of PH94B as a potential treatment of […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Data on New Preclinical Mechanism of Action Regarding Potential Anti-Anxiety Activity
October 5, 2021
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing a new generation of medicines with potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has released data regarding a new mechanism of action. The data was gathered from a preclinical tissue distribution study studying laboratory rats […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Further Advancement of PALISADE Program for PH94B in Social Anxiety Disorder
September 13, 2021
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the initiation of PALISADE-2, the second U.S. Phase 3 clinical trial to evaluate the efficacy, safety and tolerability of PH94B for the […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in Baird Global Healthcare Conference
September 8, 2021
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, will be featured in the upcoming Baird’s 2021 Global Healthcare Conference. VistaGen management, including VistaGen CEO Shawn […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Plans Q1 Financials, Corporate Update
August 13, 2021
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, released its financial and operating report for first quarter 2021, the period ended June 30, 2021. Highlights […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Plans to Release Q1 Financials, Host Earnings Call
August 10, 2021
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, will be releasing its financial and operating report for the first quarter 2021, the period ended June […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in Canaccord Genuity 41st Annual Growth Conference
August 2, 2021
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, will be participating in the upcoming Canaccord Genuity 41st Annual Growth Conference. Included in that participation will […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Strategic Board Appointment
July 22, 2021
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the appointment of Maggie FitzPatrick to its board of directors. FitzPatrick replaces Dr. Brian J. Underdown, who recently retired from the board. […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation in William Blair Biotech Focus Conference
July 9, 2021
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, will be part of this year’s online William Blair Biotech Focus Conference. VTGN management will participate in […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Key Board Appointment of Mary L. Rotunno
July 7, 2021
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the appointment of Mary L. Rotunno, J.D. to its board of directors. “Mary brings to our team more than 30 years of […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases FY 2021 Financial Results, Corporate Highlights
June 30, 2021
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has reported its financial results for fiscal year ended March 31, 2021; the company also provided a […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Conference Call to Discuss 2021 FY Results, Provide Business Update
June 25, 2021
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that it will host a conference call to provide a business update and discuss financial and operating results for its fiscal year […]
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Plans to Join Russell 2000 Index
June 17, 2021
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, will be added to the Russell 2000(R) Index effective Monday, June 28, 2021. The company will be […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Initiation of PALISADE Phase 3 Study of PH94B in SAD
May 26, 2021
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, is beginning its PALISADE-1 phase 3 trial. The randomized, double-blind, placebo-controlled study is designed to evaluate the efficacy and […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Presentation Schedule for June Investor Conferences
May 20, 2021
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that it will present at two investor conferences slated to take place in June. These include scheduled presentations, as detailed in the […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Appoints Proven Pharmaceutical Exec as Chief Commercial Officer
May 4, 2021
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the appointment of Ann Cunningham as its chief commercial officer. Cunningham, who has been and will continue serving on VTGN’s board of […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Board Appointment of Dr. Joanne Curley
April 27, 2021
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced the appointment of Joanne Curley, Ph.D. to its board of directors. VistaGen’s board will be comprised of seven directors following Dr. Curley’s […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Presents Data Regarding Drug Candidate for Replacement of Addictive Benzodiazepines
March 22, 2021
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, presented data highlighting the proposed mechanism of action (“MOA”) of its Phase 3 investigational drug candidate, PH94B nasal spray, in a poster session at […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation Schedule for Upcoming March Investor Conferences
March 16, 2021
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that its Chief Executive Officer, Shawn Singh, will participate in two investor conferences in March. For the Maxim Group and M-Vest’s Inaugural […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Preclinical Data Demonstrating Differentiated Mechanism of Action of PH10 from Benzodiazepines
March 11, 2021
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced promising preclinical data for its PH10 drug candidate. The data demonstrate that the potential mechanism of action of PH10, VistaGen’s Phase 2 investigational pherine nasal spray with potential as a rapid-onset, stand-alone treatment […]
InvestorNewsBreaks – VistaGen Therapeutics Inc.’s (NASDAQ: VTGN) Pipeline Holds Potential to Go Beyond Standard of Care for Anxiety, Depression
March 4, 2021
VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing a new generation of medications that go beyond the standard of care for anxiety and depression. A recent article discussing this reads, “Depression and anxiety are at the forefront of concern for VistaGen, a company working to develop innovative product candidates to address these […]
VistaGen Therapeutics Inc. (NASDAQ: VTGN) Committed to Developing New Generation Alternatives to Current Standard of Care for Anxiety Disorders
February 22, 2021
American Psychiatric Association poll reveals 62% of respondents have anxiety about COVID-19 Recent FDA Drug Safety Communication requires updated Boxed Warning for benzodiazepines commonly used to treat anxiety disorders VTGN is committed to developing and commercializing PH94B, a first-in-class pherine nasal spray with potential to go beyond the current standard of care for acute treatment […]
VistaGen Therapeutics Inc. (NASDAQ: VTGN) Committed to Developing New Generation of Medicines with Potential to Treat Rising Mental Health Challenges from Depression
February 18, 2021
Mental health experts note growing concern over impact of COVID-19 on nation’s mental health Compounding stress could have serious health, social consequences VTGN offers new hope to those dealing with depression disorders A new survey from the American Psychological Association (“APA”) shines a spotlight on the growing concern about the impact of the global pandemic […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q3 Financial Report, Clinical Studies Update
February 12, 2021
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has reported its financial numbers for its fiscal 2021 third quarter, ending Dec. 21, 2020. Highlights of the report are the company’s strengthened balance […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Preparing Phase 3 Trial to Evaluate Neuroactive Nasal Spray Treatment for SAD
February 10, 2021
VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, has announced plans to begin a Phase 3 clinical trial in Q2 2021. The clinical trial will evaluate PH94B (“PH94B”), a neuroactive nasal spray […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Regains Full Compliance with Nasdaq Listing Requirements
January 6, 2021
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced its receipt of notice from The Nasdaq Stock Market on Jan. 5, 2021, that VistaGen has regained compliance with the minimum bid price requirement. The requirement is under Nasdaq Listing Rule 5550(a)(2) (the […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Publication Detailing Its Investigational Neuropharmaceuticals for Anxiety and Depression Disorders
December 30, 2020
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, today announced that VistaGen Vice President, Translational Medicine Dr. Louis Monti and VistaGen CNS Clinical and Regulatory Advisory Board Member Dr. Michael Liebowitz authored an article published in CNS Spectrums, a Cambridge University Press journal. […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Featured in Equity Research Report
December 28, 2020
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in an equity research report by Maxim Group LLC. The piece discusses VistaGen’s strongest positioning yet, based on its pharmaceutical pipeline coupled with financing and a rising mental health pace. The report reads, […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Closes $100M Underwritten Public Offering
December 23, 2020
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, has announced the closing of its $100 million underwritten public offering. The offering consisted of 63,000,000 shares of its common stock at an offering price of $0.92 per share, par value $0.001 per share, and […]
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Commencement, Pricing of Underwritten Public Offering
December 18, 2020
VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, has announced the commencement and pricing of an underwritten public offering. The offering consists of 63,000,000 shares of its common stock at an offering price of $0.92 per share, par value $0.001 per share (the […]